Browsing Tag
AstraZeneca
141 posts
AstraZeneca’s Truqap, Faslodex combo recommended for EU approval for breast cancer treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Truqap (capivasertib) in…
ANGLE plc collaborates with AstraZeneca on cutting-edge cancer detection technology
ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant…
AstraZeneca posts strong Q1 2024 results with significant revenue and EPS growth
AstraZeneca PLC has reported a notable performance in the first quarter of 2024, with total revenue reaching $12,679…
Voydeya approved in EU for enhanced treatment of PNH with residual haemolytic anaemia
Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the…
AstraZeneca’s Imfinzi demonstrates significant survival benefits in Phase 3 ADRIATIC trial
In a significant advancement for cancer treatment, AstraZeneca’s Imfinzi (durvalumab) has emerged as the first and only immunotherapy…
AstraZeneca to acquire Fusion Pharmaceuticals to boost cancer radioconjugate development
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals…
AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio
AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments…
AstraZeneca achieves remarkable financial growth in 2023, fueling optimism for future innovations
AstraZeneca PLC unveiled its financial results for the fiscal year and fourth quarter of 2023 on 8 February…
AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash…
AstraZeneca, Ionis Pharmaceuticals get FDA approval of Wainua for ATTRv-PN
In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration…